Tara Lynn Kieffer Sells 2,106 Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the transaction, the insider directly owned 30,620 shares of the company’s stock, valued at $435,722.60. The trade was a 6.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA traded up $0.51 during trading hours on Friday, hitting $14.60. The stock had a trading volume of 333,749 shares, compared to its average volume of 400,542. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $15.34. The firm has a 50-day moving average price of $11.89 and a 200 day moving average price of $9.04. The firm has a market capitalization of $421.36 million, a price-to-earnings ratio of -3.81 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. The business had revenue of $15.13 million for the quarter, compared to analyst estimates of $15.60 million. As a group, analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price objective on the stock. JMP Securities boosted their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 12th. Jefferies Financial Group upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $14.00 to $20.00 in a report on Wednesday, October 1st. Evercore ISI lowered their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research note on Monday, September 15th. Finally, Westpark Capital increased their target price on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio increased its stake in Enanta Pharmaceuticals by 8.3% during the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 1,383 shares during the period. AlphaQuest LLC increased its position in shares of Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 1,562 shares during the last quarter. Sio Capital Management LLC raised its holdings in Enanta Pharmaceuticals by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock valued at $1,352,000 after buying an additional 1,770 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in Enanta Pharmaceuticals by 13.4% in the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 1,940 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.